CF PharmTech, Inc. (CF PharmTech) reported a repurchase of 72,400 H-shares on 6 October 2026, executed on the Hong Kong Stock Exchange under its existing share-buyback mandate approved on 26 June 2026.

The shares were repurchased at prices ranging between HK$6.825 and HK$7.000, translating into a volume-weighted average cost of HK$6.9007 per share. The total consideration amounted to approximately HK$0.50 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.02% to 322.02 million shares. Treasury shares increased to 1.95 million, while the total issued share count remained unchanged at 323.97 million shares as the repurchased stock is being held in treasury rather than cancelled.

Since receiving its 30.08 million-share buyback mandate, CF PharmTech has repurchased an aggregate 552,700 shares, equivalent to 0.18% of the company’s issued shares outstanding on the mandate date. In line with Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 5 November 2026.

Executive Director and Joint Company Secretary Zhu Yuyu confirmed that the repurchase complied with all applicable regulations and the terms of the shareholder-approved mandate.